GNW-Adhoc: Santhera joins GENESIS Pharma in an exclusive sales association for AGAMREE® (Vamorolon) in Zentral and Osteurope ab

^ Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) issues the Unterzeichnung an exclusive Vertriebsvereinbarung with GENESIS

NEW: 57. Activated Auflage:
>250,000 Read: Der Leitfaden für Ihr Power!
Order here for free …

Pharma für AGAMREE® (Vamorolon) for treatment of Duchenne Muscular Dystrophy

(DMD) in 20 Marken in Central and Eastern Europe.

Santhera Pharmaceuticals and GENESIS Pharma are a sales association for

20 Märkte in Mittel- en Osteurope eingangs. This strategic

Make sure to use the Soul Cover, while using uncovered medical beds,

indem GENESIS Pharma AGAMREE in Greece, Zypern, Malta, Romania,

Bulgaria, Slovakia, Croatia, Poland, Czech Republic, Ungarn,

Slovakia, Lithuania, Latvia, Estonia, Serbia, North Macedonia, Bosnia and

Herzegovina, Montenegro, Albania and Kosovo markets.

“The consultation with GENESIS Pharma is a matter of follow-up

Santhera, the worldwide sales of AGAMREE are out of order. Indem wir uns

with experts, who know the market very well,

propose optimal care for patients,” says Geert Jan

van Daal, MD, PhD, Chief Commercial Officer of Santhera. “It’s a different story

Step in our strategy, our own Santhera Teams are dying

European Schlüsselmärkte zu konzentrieren en gleichzeitig Partnerschaften

with the best aspects for the European Nicht-Kernmärkte einzugehen.”

Constantinos Evripides, Managing Director of GENESIS Pharma, stated: “Unser

Internal health has a strong focus on certain diseases and improves it

a more as zwanzigjährige Erfahrung in der Vermarktung von Orphan-Therapien.

We are happy together and enjoy our experiences in the CEE region

trust and our damn worth, our breadth and robustness

Wallet for a select amount of money in a different way. We were nld and

gewissenhaft mit Santhera zammenarbeiten, een einen reibungslosen and

Make sure you are not hindered by all the patients you need, the spark of it

innovative treatment could be profitable.”

The European Commission has approved AGAMREE for consideration in December 2023

DMD in patients for 4 years. Basis for this were the Data of the

positive DMD adoption study and more offender studies. Patients who mit

AGAMREE or Placebo were heated, said to be normal and dry

Wachstum, während bij Kindern, who were discussed with Prednisone, a

Wachstumsverzögerung is carried out. Darüber hinaus beielten Patients, dying

Or a standard short-term corticosteroid can be administered to AGAMREE

Work in the form of a cavity in your Wachstum and in your Knochengesundheit.

About AGAMREE® (Vamorolone)

AGAMREE is a new device with a working mechanism that works on the

Tie a closed receptacle with a short discount, if you do that

mock active change. There is no substrate for the 11-?-

Hydroxysteroid Dehydrogenase (11?-HSD) Enzyme, which provides local erection

Wirkstoffspiegel and the short steroid-associated toxicity in local networks

responsible signal dürften (1-4). Dieser Mechanismus hat das Potenzial, dice

Wirksamkeit of the safety considerations given to steroids during coupling,

weshalb AGAMREE als dissoziatieve Entzündungshemmer und Alternative zu den

best short steroids, the timely standard therapy for children and

Jugendliche mit DMD, positioniert ist (1-4).

In the relevant VISION-DMD study, AGAMREE is the main

End point of upward movement (TTSTAND) in Placebo view

(p=0.002) after 24 treatment sessions and said they were good health and safety

Verträglichkeitsprofile (1, 4). Those who were the worst reported Nebenwirkungen were

cushingoides Aussehen, Erbrechen, Weightzunahme und Reizbarkeit. I am

All parts were die Nebenwirkungen von leichtem bis mittlerem Schweregrad.

Die derzeit verügbaren Daten see, that AGAMREE in Gegensatz zu

Short steroids on the waiting list are not good (5) and not negative

Wirkungen on the Knochenstoffwechsel hat, was normally Serummarker for

Knochenbildung und -resorption is invested (6).

AGAMREE (Vamorolone), a medicine for selected diseases, is in the US

(prescribing information (https://agamree.com/pdf/agamree-pi.pdf)), der

European Union (Zusammenfassung der Merkmale des Arzneimittels

(https://www.ema.europa.eu/de/documents/product-information/agamree-epar-

product-information_de.pdf)) and in the Vereinigten Königreich für die Anwendung

allow.

Literature reference:

(1) Dang UJ et al. (2024) Neurology 2024;102:e208112.

doi.org/10.1212/WNL.0000000000208112. Link

(https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000208112).

(2) Guglieri M et al. (2022). JAMA Neurol. 2022;79(10):1005-1014.

doi:10.1001/jamaneurol.2022.2480. Link

(https://jamanetwork.com/journals/jamaneurology/fullarticle/2795868?utm_campaign

=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaneur

(ol.2022.2480).

(3) Liu X et al (2020). Proc Natl Acad Sci USA 117:24285–24293

(4) Heier CR et al (2019). Life Science Alliance DOI: 10.26508

(5) Ward et al., WMS 2022, FP.27 – Poster 71. Link

(https://www.santhera.com/assets/files/content/scientific-literature/P71-

SAN1122002_WMS_Hoogte_Poster_30x42_v6.09534-FINAL-cm3.pdf).

(6) Hasham et al., MDA 2022 Posterpresentation. Link

(https://www.santhera.com/assets/files/content/scientific-literature/SAN1122001-

PDN switch-Poster_14Mar22.pdf).

Uber Duchenne Muscular Dystrophy

Duchenne-Muskel dystrophy (DMD) is a rare condition caused by the X chromosome

stipulated Erbkrankheit, die fast ausschliesslich Manner. DMD is expensive

A task has been performed that is at the beginning or the end of the day.

Treatment of Muskeln’s fibrosis and clinical management

due to severe musculoskeletal degeneration and schwäche. White Meilensteine

of insanity since the delight of God, of the delight of

Self-empowerment, the beginning of assistance in defeating and the development of a

Cardiomyopathy. DMD reduces the Lebenserwartung of Atem and/or others

Reversals for their celebrations of life. Short steroids are there

sixth standard for the treatment of DMD.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Schweizer

Special pharmaceutical products that are responsible for the development and marketing of

innovative drugs for selenium neuromuscular and pulmonary diseases

With medical care, special care. The Unternehmen hat von

ReveraGen an exclusive Lizenz for all indications for AGAMREE®

(Vamorolone), a dissociative steroid with novel action, which in

a trial study in patients with Duchenne-Muskel dystrophy (DMD) as

Alternative to standard short steroids that are not researched. AGAMREE is for death

Treatment of DMD in the US by the Food and Drug Administration (FDA), in der

EU von der European Medicines Agency (EMA) und in Grossbritannien von der

Medicines and Healthcare products Regulatory Agency (MHRA) zugelassen. Santhera

as to the rights of AGAMREE for North America and Catalyst Pharmaceuticals and for

China and Sperogenix Therapeutics have been merged. For more information

Visit our website www.santhera.com.

AGAMREE® is a Brand of Santhera Pharmaceuticals.

About GENESIS Pharma

GENESIS Pharma is a regional biopharmaceutical company that is active in the market

Marketing of innovative biopharmaceutical products for the treatment of products and products

Seltener Krankheiten in Mittel- und Osteuropa konzentriert. GENESIS Pharma Wurde

1997 Gegründet und War Eines der Ersten Pharmazeutischen Unternehmen in Europa,

that is the marketing, sales and distribution of biopharmaceutical products

special hat. GENESIS Pharma has a strong portfolio in hand

Therapy areas with its medical treatment through long-term strategic

Alliances with a well-developed biopharmaceutical product. For more

Information about this website www.genesispharmagroup.com

(http://www.genesispharmagroup.com).

For more information, please read the following:

(email protected) (mailto:(email protected)) or

Eva Kalias, Head of Investor Relations & Communications

Phone: +41 79 875 27 80

(email address)

For more information about GENESIS Pharma, please know:

Natalia Karahaliou, Communications Manager

(email address) (mailto:(email address))

Phone: +30 210 87 71 605

Haftungsausschluss / Zukunftsgerichtete Aussagen

This Mitteilung again states neither an Angebot nor an Aufforderung zur Zeichnung

or zum Kauf von Wertpapers from Santhera Pharmaceuticals Holding AG dar.

This publication can provide the best results

Unternehmen en seine Geschäftstätigkeit enthalten. Solche Aussagen since mit

bestimmten Risiken, Unsicherheiten and other Factors verunden, die dazu

to be able to live, to have valuable experience, finance, and learning

or errungenschaften des Unternehmens wesentlich von denjenigen abweichen, die

were brought or implied in the sollchen Aussagen zum Ausdruck. Die Leser

sollten seich daher nicht in unangemessener Weise auf diese Aussagen verlassen,

especially not in Zusammenhang mit Verträgen oder

Investitionsentscheidungen. Das Unternehmen lehnt jede Verpflichtung ab, diese

Zukunftsgerichten Aussagen zu updated.

###

°

Source: dpa-AFX